Early Prevention and Precision Management of Female Fertility Decline

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age20-40
SponsorPeking University Third Hospital

About this trial

Female fertility decline has become an important public health issue in China, with a substantial proportion of women of reproductive age experiencing reduced ovarian reserve. However, effective tools for early identification and large-scale prevention of fertility impairment in the general population are still lacking.

This study aims to develop and evaluate a precision prevention strategy for early female fertility decline based on the OvaRePred-Plus model, which integrates ovarian reserve markers, lifestyle factors, and reproductive health indicators. A multicenter, cluster randomized controlled trial will be conducted across six medical centers in China, enrolling women aged 20-40 years identified as having early signs of fertility decline.

Participants will be allocated to either an intervention group receiving a comprehensive health management program (including dietary optimization, nutritional supplementation, physical activity, and sleep improvement) or a control group receiving routine clinical care. The intervention will last for 12 weeks.

The primary outcome is the change in fertility score assessed by the OvaRePred-Plus model. Secondary outcomes include changes in ovarian reserve markers (e.g., AMH), menstrual status, ultrasound parameters, and reproductive outcomes.

This study is expected to provide evidence for a scalable and cost-effective strategy for early prevention and management of female fertility decline.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women aged 20-40 years

Diagnosed with infertility or planning assisted reproductive treatment

Regular menstrual cycles (21-35 days)

Willing to participate in a 12-week lifestyle intervention program

Disqualifiers

Known chromosomal abnormalities or genetic disorders affecting fertility

History of ovarian surgery or severe ovarian damage

Diagnosed endocrine disorders affecting reproduction (e.g., uncontrolled thyroid disease, hyperprolactinemia)

Severe systemic diseases (e.g., cardiovascular, hepatic, renal diseases)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Comprehensive Lifestyle Intervention

    Behavioral

    A 12-week structured lifestyle intervention program designed to improve female reproductive health. The intervention includes dietary optimization (high-protein, high-vitamin, low-fat diet), nutritional supplementation (vitamin C, vitamin D, and folic acid), structured physical activity (at least 150 minutes of moderate-intensity exercise per week), and sleep improvement (7-8 hours per night with optimized sleep timing). The program is supported by biweekly health education sessions and digital monitoring tools to enhance adherence and behavior change.

  • Routine Clinical Care

    Other intervention

    Participants receive standard clinical management, including medical history assessment, hormonal testing, ultrasound evaluation, and general health education, without a structured lifestyle intervention program.

Treatment groups

384 Participants
are divided into 2 treatment groups
Group A: Intervention GroupExperimental treatment 1 intervention
Group B: Control GroupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in Ovarian Reserve Score (OvaRePred) After 12 Weeks

Time frame
Baseline to 12 weeks

Secondary outcomes

1

Change in Anti-Müllerian Hormone (AMH) Levels

Time frame
Baseline to 12 weeks
2

Change in Antral Follicle Count (AFC)

Time frame
Baseline to 12 weeks
3

Change in Reproductive Hormone Levels

Time frame
Baseline to 12 weeks

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: